Life Science Investing Incyte Japan Announces Approval of Minjuvi® in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Life Science Investing Incyte Japan Announces Approval of Zynyz® for the First-Line Treatment of Advanced Anal Cancer
Life Science Investing Incyte Announces European Commission Approval of Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma
Life Science Investing Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Life Science Investing Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
Life Science Investing Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
Life Science Investing Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
Life Science Investing Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
Life Science Investing Incyte Announces Positive CHMP Opinion for Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma
Life Science Investing Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
Life Science Investing Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Life Science Investing Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
